Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2014-04-16 16:44:33
Reporting Period:
Filing Date:
Accepted Time:
2014-04-16 16:44:33
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
912183 Cubist Pharmaceuticals Inc CBST Pharmaceutical Preparations (2834) 223192085
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1435744 Thomas Desrosier 65 Hayden Avenue
Lexington MA 02421
Evp, Chief Legal No Yes No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-04-15 2,377 $0.00 2,377 No 4 M Direct
Common Stock Disposition 2014-04-16 768 $64.00 1,609 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2014-04-15 2,377 $0.00 2,377 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,132 2014-04-15 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 342 Indirect 401(k) Plan
  1. Sold pursuant to a Rule 10(b)5-1 Plan.
  2. Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.
  3. This transaction was executed in multiple trades at prices ranging from $64.0600 to $64.0000. The price reported in the table reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
  4. Each restricted stock unit represents a contingent right to receive one share of Cubist common stock for no consideration.
  5. The restricted stock units vest 25% annually over a four-year period, with the first 25% vesting one year after the grant date. The restricted stock units do not expire.